Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease

BACKGROUND: Low anti-tumor necrosis factor α (TNFα) serum concentrations may result in lack of treatment response in patients with inflammatory bowel disease. We determined the anti-TNFα drug concentrations in patients with inflammatory bowel disease and investigated whether or not subtherapeutic dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsen, Arne, Omdal, Roald, Leitao, Kristian Øgreid, Isaksen, Kjetil, Hetta, Anne Kristine, Karlsen, Lars Normann, Aabakken, Lars, Bolstad, Nils, Warren, David, Lundin, Knut E.A., Grimstad, Tore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881967/
https://www.ncbi.nlm.nih.gov/pubmed/29623105
http://dx.doi.org/10.1177/1756284818759930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881967/
https://www.ncbi.nlm.nih.gov/pubmed/29623105
http://dx.doi.org/10.1177/1756284818759930

Ejemplares similares